CN116194133A - 抗gd2 sada缀合物及其用途 - Google Patents

抗gd2 sada缀合物及其用途 Download PDF

Info

Publication number
CN116194133A
CN116194133A CN202180059161.6A CN202180059161A CN116194133A CN 116194133 A CN116194133 A CN 116194133A CN 202180059161 A CN202180059161 A CN 202180059161A CN 116194133 A CN116194133 A CN 116194133A
Authority
CN
China
Prior art keywords
dota
seq
lys
sada
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180059161.6A
Other languages
English (en)
Chinese (zh)
Inventor
B·H·桑迪奇
N·K·V·张
M·阿赫麦德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN116194133A publication Critical patent/CN116194133A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180059161.6A 2020-05-27 2021-05-26 抗gd2 sada缀合物及其用途 Pending CN116194133A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063030591P 2020-05-27 2020-05-27
US63/030,591 2020-05-27
PCT/US2021/034230 WO2021242848A1 (en) 2020-05-27 2021-05-26 Anti-gd2 sada conjugates and uses thereof

Publications (1)

Publication Number Publication Date
CN116194133A true CN116194133A (zh) 2023-05-30

Family

ID=78722708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180059161.6A Pending CN116194133A (zh) 2020-05-27 2021-05-26 抗gd2 sada缀合物及其用途

Country Status (7)

Country Link
US (1) US20230235087A1 (https=)
EP (1) EP4157293A4 (https=)
JP (1) JP2023527385A (https=)
CN (1) CN116194133A (https=)
AU (1) AU2021280272A1 (https=)
CA (1) CA3180445A1 (https=)
WO (1) WO2021242848A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11583588B2 (en) * 2017-05-05 2023-02-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (SADA) technologies
EP4448565A1 (en) 2021-12-15 2024-10-23 Y-Mabs Therapeutics, Inc. Scfv and antibodies with reduced multimerisation
JP2024546804A (ja) * 2021-12-15 2024-12-26 ワイ－マブス セラピューティクス， インコーポレイテッド Ｓａｄａ複合体を含む製剤
US20260021206A1 (en) * 2022-07-25 2026-01-22 Vironexis Biotherapeutics Inc. Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
CN111050808A (zh) * 2017-07-06 2020-04-21 纪念斯隆-凯特林癌症中心 用于抗dota/抗肿瘤抗原双特异性抗体预靶向放射免疫治疗的dota-半抗原组合物
US20200155698A1 (en) * 2017-05-05 2020-05-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (sada) technologies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
EP3765031A4 (en) * 2018-03-14 2022-03-23 Memorial Sloan Kettering Cancer Center ANTI-POLYSIAL ACID ANTIBODIES AND USES THEREOF
AU2020225631A1 (en) * 2019-02-22 2021-09-16 Memorial Sloan Kettering Cancer Center CD33 antibodies and methods of using the same to treat cancer
EP3938400B1 (en) * 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
CN114401744B (zh) * 2019-06-26 2024-11-05 纪念斯隆凯特琳癌症中心 用于治疗癌症的抗cd33抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
US20200155698A1 (en) * 2017-05-05 2020-05-21 Memorial Sloan Kettering Cancer Center Modular self assembly disassembly (sada) technologies
CN111050808A (zh) * 2017-07-06 2020-04-21 纪念斯隆-凯特林癌症中心 用于抗dota/抗肿瘤抗原双特异性抗体预靶向放射免疫治疗的dota-半抗原组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRIAN SANTICH等: "Self-Assembling and DisAssembling Bispecific Antibodiesfor Curative 2-step Pretargeted Radioimmunotherapy", JOURNAL OF NUCLEAR MEDICINE, vol. 61, no. 1, 15 May 2020 (2020-05-15), pages 1 - 2 *

Also Published As

Publication number Publication date
EP4157293A4 (en) 2024-07-31
US20230235087A1 (en) 2023-07-27
JP2023527385A (ja) 2023-06-28
EP4157293A1 (en) 2023-04-05
WO2021242848A1 (en) 2021-12-02
CA3180445A1 (en) 2021-12-02
AU2021280272A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
CN116194133A (zh) 抗gd2 sada缀合物及其用途
US8491896B2 (en) Anti-pancreatic cancer antibodies
JP5919604B2 (ja) 抗膵癌抗体
CN107847584B (zh) 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途
JP2022540385A (ja) 新生児ｆｃ受容体に対する低下した親和性を有する、ｐｓｍａに結合するための抗体
US9989524B2 (en) Immuno imaging agent for use with antibody-drug conjugate therapy
BR112020018560A2 (pt) Agentes de ligação bi específicos e usos dos mesmos
JP2024519970A (ja) 三価放射性同位体生物標的放射性医薬品、調製方法及び使用
CN116655793A (zh) Bcma特异性诊疗一体化分子影像探针的制备方法及应用
US8821868B2 (en) Anti-pancreatic cancer antibodies
EP2953977B1 (en) Immuno imaging agent for use with antibody-drug conjugate therapy
US9844607B2 (en) Immuno imaging agent for use with antibody-drug conjugate therapy
EP2953975B1 (en) Immuno imaging agent for use with antibody-drug conjugate therapy
EP4317188A1 (en) Radioactive complex of anti-egfr antibody, and radiopharmaceutical
US20170137534A1 (en) Anti-Pancreatic Cancer Antibodies
WO2025111661A1 (en) Novel radiolabelled antibodies
TW202606757A (zh) 用於治療前列腺癌之組成物及方法
WO2025035107A2 (en) Trophoblast glycoprotein antibody compositions and methods of use
US9599619B2 (en) Anti-pancreatic cancer antibodies
HK40105645A (zh) 用於治疗前列腺癌的组合物和方法
CN117396234A (zh) 用于治疗前列腺癌的组合物和方法
EP4149543A1 (en) Anti-cd38 single-domain antibodies in disease monitoring and treatment

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination